India cracks down on unauthorized sale of GLP-1 weight-loss drugs, intensifies surveillance

In order to ensure ethical pharmaceutical practices in the supply chain of weight-loss drugs (GLP-1), the Drugs Controller of India has intensified regulatory surveillance against their unauthorized sale and promotion.

With the recent introduction of multiple generic variants of GLP-1-based weight-loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics.

Advertisement

These drugs, when used without proper medical supervision, may lead to serious adverse effects and associated health risks.

Taking cognizance of the situation, India’s Drugs Controller, in collaboration with state regulators, has initiated a series of targeted actions to curb potential malpractices across the pharmaceutical supply chain and prevent unauthorized sales and misuse.

On March 10, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label use.

In recent weeks, enforcement activities have been significantly scaled up. Audits and inspections were conducted at 49 entities, including online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics.

These inspections spanned multiple regions across the country and focused on identifying violations related to unauthorized sales, improper prescription practices, and misleading marketing. Notices have also been issued to defaulting entities.

The regulator emphasized that patient safety remains paramount. The misuse of weight-loss drugs without clinical oversight can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical practitioners.

“It is important to reiterate that the drug has been approved in India with the condition that it be prescribed only by endocrinologists and internal medicine specialists, and for certain indications, by cardiologists. Regulatory surveillance will continue to be intensified in the coming weeks, and non-compliance will be dealt with strictly through actions including cancellation of licenses, penalties, and prosecution under applicable laws,” an official press note said on Tuesday.